Deal To Fight Zika Virus Boosts NIH, CDC Efforts, But Offers No FDA Review Dollars
This article was originally published in The Gray Sheet
Executive Summary
A $1.1bn agreement between the House and Senate to fund the emergency Zika virus response gives millions of dollars to the Centers for Disease Control and Prevention, NIH, and HHS's biodefense unit, but leaves FDA with no extra funds to support reviews of Zika products. The deal would take dollars from Ebola funding and HHS Affordable Care Act efforts as an offset, and is opposed by the president, who says he will veto it.